Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood D. Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016
Cited by 645 works. doi:10.1016/s1470-2045(16)30508-3
Authors
- Glenwood D. Goss
- Chun‐Ming Tsai
- Frances A. Shepherd
- Lyudmila A. Bazhenova
- Jong Seok Lee
- Gee‐Chen Chang
- Lucio Crinò
- Miyako Satouchi
- Quincy Siu-Chung Chu
- Toyoaki Hida
- Ji‐Youn Han
- Óscar Juan
- Frank Dunphy
- Makoto Nishio
- Jin‐Hyoung Kang
- Margarita Majem
- Helen Mann
- Mireille Cantarini
- Serban Ghiorghiu
- Tetsuya Mitsudomi
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Interpreting the significance of changes in health-related quality-of-life scores.
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- EORTC QLQ-C30 Scoring Manual
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib